964 results on '"Van Poppel, Hein"'
Search Results
102. Is partial nephrectomy a better surgical option for the treatment of renal cell carcinoma?
103. The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients
104. Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology
105. Indications for radical prostatectomy
106. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
107. A Critical Need for National Guidelines
108. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy
109. Efficacy and safety of nephron-sparing surgery
110. VALUE OF ELND IN LYMPH NODE NEGATIVE PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER IS UNCERTAIN: 1061
111. TIME TO BIOCHEMICAL RECURRENCE IS A STRONG AND INDEPENDENT PREDICTOR OF CSS AND OS IN HIGH-RISK PROSTATE CANCER: 1063
112. PREDICTING PROSTATE CANCER SPECIFIC OUTCOME AFTER RADICAL PROSTATECTOMY AMONG MEN WITH PSA &[GE] 20 NG/ML WITH OR WITHOUT ADDITIONAL HIGH RISK FACTORS: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 712 PATIENTS: 578
113. A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity
114. Outcome of nephron-sparing surgery for T1b renal cell carcinoma
115. OUTCOME OF MULTIMODALITY TREATMENT WITH RADICAL PROSTATECTOMY AS INITIAL STEP FOR PROSTATE CANCER WITH PSA >20 NG/ML: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 801 PATIENTS: 1279
116. Prepubic urethrectomy
117. Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy
118. Surgery for Clinical T3 Prostate Cancer
119. Advanced prostate cancer: place of surgery
120. Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
121. Is nephron-sparing surgery as safe and effective as radical nephrectomy in patients with locally advanced RCC?
122. QUALITY CONTROL IN NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY – RESULTS OF THE EUROPEAN SOCIETY OF ONCOLOGICAL UROLOGY (ESOU): 1892
123. CLINICAL T3 PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: RESULTS FROM THE EUROPEAN SOCIETY OF ONCOLOGICAL UROLOGY (ESOU): 1629
124. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?
125. Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b)
126. Should the pT2 tumor classification for renal cell carcinoma be subdivided according to tumor size?
127. Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathy
128. Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy
129. Chemotherapy for older patients with prostate cancer
130. Detection of clinical unilateral T3a prostate cancer – by digital rectal examination or transrectal ultrasonography?
131. The indications for partial nephrectomy in the treatment of renal cell carcinoma
132. Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
133. Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery
134. Conservative vs radical surgery for renal cell carcinoma
135. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis
136. Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy
137. Radical cystectomy with or without urethrectomy?
138. Clinical Results of Radical Prostatectomy
139. MP22-01 WHAT IS THE BEST DEFINITION OF BIOCHEMICAL RESPONSE TO SALVAGE RADIATION THERAPY IN PROSTATE CANCER PATIENTS TREATED FOR PSA RISING AFTER RADICAL PROSTATECTOMY? RESULTS FROM A MULTI-INSTITUTIONAL SERIES
140. MP22-06 IMAGING TARGETED TREATMENTS VERSUS EXTENDED SALVAGE LYMPH NODE DISSECTION FOR PATIENTS WITH A SINGLE NODAL RECURRENCE OF PROSTATE CANCER: A COMPARATIVE ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES
141. MP22-03 LONG-TERM ONCOLOGIC OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES
142. PD17-08 COMPARING THE DIAGNOSTIC ACCURACY OF 68GA-PSMA AND 11C-CHOLINE PET/CTSCAN ACCORDING TO PSA LEVEL: A LARGE MULTI-INSTITUTIONAL ANALYSIS WITH HISTOLOGICAL VERIFICATION IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER
143. PD15-04 THERE IS NO WAY TO COMPENSATE FOR A NON-TIMELY USE OF SALVAGE RADIATION THERAPY IN MEN WITH RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
144. PD45-10 IMPACT OF CLINICAL TUMOR STAGE AND PREOPERATIVE PSA-VALUE ON CANCER SPECIFIC SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH GLEASON 9-10 ON PROSTATE BIOPSY.
145. Chromosome changes in sarcomatoid renal carcinomas are different from those in renal cell carcinomas
146. RADICAL PROSTATECTOMY FOR PSA-DETECTED STAGE T1c PROSTATE CANCER-IT COULD BE BETTER AFTER TUMOR STRATIFICATION
147. A WARRANTED INDICATION OF FREE/TOTAL (F/T) PROSTATE SPECIFIC ANTIGEN(PSA) RATIO MEASUREMENT FOR DIAGNOSIS OF IMPALPABLE STAGE T1c PROSTATE CANCER(CaP)
148. SERUM TISSUE POLYPEPTIDE ANTIGEN (TPA): A VALUABLE MARKER FOR MONITORING TRANSITIONAL CELL CARCINOMA
149. Is a 1- cm margin necessary during nephron-sparing surgery for renal cell carcinoma?
150. Involvement of Chromosomes 1 and 18 in Renal Cell Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.